05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
00:07 , Sep 28, 2018 |  BC Innovations  |  Tools & Techniques

Deconstructing tox in immuno-oncology

The best route to improving preclinical toxicity in immunotherapies could lie in reverse translation, feeding clinical data back into the preclinical space to inform model development, rather than trying to guess a priori what the...
16:41 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
18:15 , Aug 31, 2018 |  BC Extra  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
19:42 , May 18, 2018 |  BC Week In Review  |  Clinical News

Novartis to start head-to-head trial of Cosentyx and Tremfya

Novartis AG (NYSE:NVS; SIX:NOVN) plans to begin the head-to-head Phase IIa ARROW trial to compare Cosentyx secukinumab to Tremfya guselkumab for 16 weeks in 40 patients with Stelara ustekinumab-resistant plaque psoriasis. The pharma expects to...
21:48 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Novartis' canakinumab reduces CV risk in CANTOS subgroup

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from a subgroup of patients who achieved a high sensitivity C-reactive protein (hsCRP) level of <2 mg/L at three months after the first dose of subcutaneous canakinumab (ACZ885) in...
23:20 , Nov 9, 2017 |  BC Week In Review  |  Clinical News

J&J's Stelara headed for Phase III in lupus

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) said Stelara ustekinumab (CNTO 1275) met the primary endpoint of improving lupus disease activity in a Phase II trial to treat systemic lupus...
19:55 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab (ACZ885) significantly reduced lung cancer incidence and associated mortality vs. placebo in the Phase III CANTOS cardiovascular outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis....
19:38 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

Novartis' canakinumab reduces CV risk in MI patients

Novartis AG (NYSE:NVS; SIX:NOVN) reported top-line data from the Phase III CANTOS trial in 10,061 patients who had a prior myocardial infarction (MI) and inflammatory atherosclerosis showing that subcutaneous Ilaris canakinumab (ACZ885) plus standard of...
19:54 , May 12, 2017 |  BC Week In Review  |  Company News

NICE issues positive FAD for Stelara

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Stelara ustekinumab from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) to treat adults with moderate to severely active Crohn's...